T. Rowe Price Associates
MRSN

T. Rowe Price Associates’s Mersana Therapeutics MRSN Stock Holding History

T. Rowe Price Associates’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,484
Closed -$22K – 3115
2025
Q1 		$22K Hold
2,484
– – ﹤0.01% 3001
2024
Q4 		$89K Sell
2,484
-1,479
-37% -$76.5K ﹤0.01% 2854
2024
Q3 		$188K Hold
3,963
– – ﹤0.01% 2668
2024
Q2 		$200K Buy
3,963
+766
+24% +$55.4K ﹤0.01% 2593
2024
Q1 		$359K Buy
3,197
+198
+7% +$19.7K ﹤0.01% 2349
2023
Q4 		$174K Sell
2,999
-486
-14% -$19.6K ﹤0.01% 2589
2023
Q3 		$111K Sell
3,485
-1,289
-27% -$61.3K ﹤0.01% 2642
2023
Q2 		$394K Sell
4,774
-81
-2% -$11.8K ﹤0.01% 2242
2023
Q1 		$500K Buy
4,855
+34
+0.7% +$4.77K ﹤0.01% 2106
2022
Q4 		$707K Buy
4,821
+339
+8% +$57.3K ﹤0.01% 1968
2022
Q3 		$758K Sell
4,482
-1,111
-20% -$181K ﹤0.01% 1909
2022
Q2 		$646K Buy
5,593
+72
+1% +$6.77K ﹤0.01% 2105
2022
Q1 		$551K Buy
5,521
+943
+21% +$110K ﹤0.01% 2291
2021
Q4 		$712K Sell
4,578
-34,658
-88% -$6.74M ﹤0.01% 2210
2021
Q3 		$9.25M Sell
39,236
-53,474
-58% -$15.6M ﹤0.01% 1427
2021
Q2 		$31.5M Sell
92,710
-26,253
-22% -$9.94M ﹤0.01% 1180
2021
Q1 		$48.1M Sell
118,963
-13,211
-10% -$6.41M ﹤0.01% 1016
2020
Q4 		$87.9M Buy
132,174
+59,029
+81% +$32.8M 0.01% 771
2020
Q3 		$34M Buy
73,145
+43,336
+145% +$21.9M ﹤0.01% 999
2020
Q2 		$17.4M Buy
+29,809
New +$10.2M ﹤0.01% 1180

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates's MRSN Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 2,484 shares — an estimated $22K sold.

T. Rowe Price Associates first reported a position in MRSN in Q2 2020 and held it in 20 quarters. The position peaked at $87.9M in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,484 Mersana Therapeutics shares in Q2 2025, an estimated $22K.
  • T. Rowe Price Associates first reported a position in Mersana Therapeutics in Q2 2020 and held it in 20 quarters.
  • T. Rowe Price Associates's Mersana Therapeutics position peaked at $87.9M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.